{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:22:11Z","timestamp":1788351731694,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking University International Hospital In-Hospital Research Fund","award":["YN2024QX02"],"award-info":[{"award-number":["YN2024QX02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04462-9","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:47:19Z","timestamp":1782096439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting RELA and STAT3 regulates TNFRSF10A-mediated apoptosis in a novel apoptosis-based prognostic model for clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuyou","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"4462_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","volume":"17","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Jonasch E, Michaelson MD, et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019;17:1278\u201385.","journal-title":"J Natl Compr Canc Netw"},{"key":"4462_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4462_CR3","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"4462_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888\u201398.","journal-title":"Lancet Oncol"},{"key":"4462_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","volume":"18","author":"Y Xue","year":"2021","unstructured":"Xue Y, Gao S, Gou J, et al. Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18:187\u2013203.","journal-title":"Expert Opin Drug Deliv"},{"key":"4462_CR6","doi-asserted-by":"publisher","first-page":"567730","DOI":"10.3389\/fmolb.2021.567730","volume":"8","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen Y, Zhu B, Ma L, Xing Q. A novel nine apoptosis-related genes signature predicting overall survival for kidney renal clear cell carcinoma and its associations with immune infiltration. Front Mol Biosci. 2021;8:567730.","journal-title":"Front Mol Biosci"},{"key":"4462_CR7","doi-asserted-by":"publisher","first-page":"1161666","DOI":"10.3389\/fonc.2023.1161666","volume":"13","author":"G Xia","year":"2023","unstructured":"Xia G, Wu S, Cui X. An immune infiltration-related prognostic model of kidney renal clear cell carcinoma with two valuable markers: CAPN12 and MSC. Front Oncol. 2023;13:1161666.","journal-title":"Front Oncol"},{"key":"4462_CR8","doi-asserted-by":"publisher","first-page":"e24903","DOI":"10.1097\/MD.0000000000024903","volume":"100","author":"L Wang","year":"2021","unstructured":"Wang L, Gu W, Ni H. Construction of a prognostic value model in papillary renal cell carcinoma by immune-related genes. Med (Baltim). 2021;100:e24903.","journal-title":"Med (Baltim)"},{"key":"4462_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"4462_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337\u201344.","journal-title":"Biometrics"},{"key":"4462_CR11","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52:D174\u201382.","journal-title":"Nucleic Acids Res"},{"key":"4462_CR12","doi-asserted-by":"publisher","first-page":"102167","DOI":"10.1016\/j.clgc.2024.102167","volume":"22","author":"D Yang","year":"2024","unstructured":"Yang D. Prognostic model and immune response of clear cell renal cell carcinoma based on co-expression genes signature. Clin Genitourin Cancer. 2024;22:102167.","journal-title":"Clin Genitourin Cancer"},{"key":"4462_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1186\/s12885-023-11150-4","volume":"23","author":"Z Gui","year":"2023","unstructured":"Gui Z, Du J, Wu N, et al. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma. BMC Cancer. 2023;23:649.","journal-title":"BMC Cancer"},{"key":"4462_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s13167-023-00327-3","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Shi Y, Zhang Y. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework. EPMA J. 2023;14:275\u2013305.","journal-title":"EPMA J"},{"key":"4462_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108\u201312.","journal-title":"Nature"},{"key":"4462_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486\u2013541.","journal-title":"Cell Death Differ"},{"key":"4462_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4462_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"4462_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12935-021-01830-1","volume":"21","author":"S Chen","year":"2021","unstructured":"Chen S, Yu M, Ju L, et al. The immune-related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation. Cancer Cell Int. 2021;21:119.","journal-title":"Cancer Cell Int"},{"key":"4462_CR20","first-page":"163","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wu Y, Cai A, et al. Cisplatin inhibits the proliferation of Saos-2 osteosarcoma cells via the miR-376c\/TGFA pathway. Bosn J Basic Med Sci. 2021;21:163\u201373.","journal-title":"Bosn J Basic Med Sci"},{"key":"4462_CR21","doi-asserted-by":"publisher","first-page":"7102736","DOI":"10.1155\/2022\/7102736","volume":"2022","author":"H Jin","year":"2022","unstructured":"Jin H, Liu W, Xu W, et al. Identification of prognostic factors in cholangiocarcinoma based on integrated ceRNA network analysis. Comput Math Methods Med. 2022;2022:7102736.","journal-title":"Comput Math Methods Med"},{"key":"4462_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2021.05.006","volume":"514","author":"OK Provance","year":"2021","unstructured":"Provance OK, Geanes ES, Lui AJ, et al. Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer Lett. 2021;514:12\u201329.","journal-title":"Cancer Lett"},{"key":"4462_CR23","doi-asserted-by":"publisher","first-page":"110868","DOI":"10.1016\/j.cellsig.2023.110868","volume":"111","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang W, Ding Z, et al. SEMA3G functions as a novel prognostic biomarker associated with Wnt pathway in clear cell renal cell carcinoma. Cell Signal. 2023;111:110868.","journal-title":"Cell Signal"},{"key":"4462_CR24","doi-asserted-by":"publisher","first-page":"113106","DOI":"10.1016\/j.intimp.2024.113106","volume":"142","author":"T Huang","year":"2024","unstructured":"Huang T, Peng Y, Liu R, et al. Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. Int Immunopharmacol. 2024;142:113106.","journal-title":"Int Immunopharmacol"},{"key":"4462_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.15673","volume":"130","author":"JA Usher-Smith","year":"2022","unstructured":"Usher-Smith JA, Li L, Roberts L, et al. Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int. 2022;130:562\u201379.","journal-title":"BJU Int"},{"key":"4462_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.pathol.2018.03.003","volume":"50","author":"KL Ng","year":"2018","unstructured":"Ng KL, Yap NY, Rajandram R, et al. Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients. Pathology. 2018;50:511\u20138.","journal-title":"Pathology"},{"key":"4462_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jare.2024.07.030","volume":"72","author":"NA Jayab","year":"2025","unstructured":"Jayab NA, Abed A, Talaat IM, Hamoudi R. The molecular mechanism of NF-kappaB dysregulation across different subtypes of renal cell carcinoma. J Adv Res. 2025;72:501\u201314.","journal-title":"J Adv Res"},{"key":"4462_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2174\/0113895575254012231024062619","volume":"24","author":"S Arun","year":"2024","unstructured":"Arun S, Patel PK, Lakshmanan K, Rajangopal K, Swaminathan G, Byran G. Targeting STAT3 enzyme for cancer treatment. Mini Rev Med Chem. 2024;24:1252\u201361.","journal-title":"Mini Rev Med Chem"},{"key":"4462_CR29","doi-asserted-by":"publisher","first-page":"215880","DOI":"10.1016\/j.canlet.2022.215880","volume":"547","author":"X Wang","year":"2022","unstructured":"Wang X, Hu R, Song Z, et al. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Lett. 2022;547:215880.","journal-title":"Cancer Lett"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04462-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04462-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04462-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:03:28Z","timestamp":1788350608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04462-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4462"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04462-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data used in this study were obtained from the publicly available TCGA and ICGC databases. All datasets are de-identified and publicly accessible. Therefore, ethical approval and informed consent were not required for this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"355"}}